Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679650 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
A Phase 1 study of Acute Myelogenous Leukemia, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT03679650 is a Phase 1 study of Acute Myelogenous Leukemia that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 28 participants, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03679650, a Phase 1 study of Acute Myelogenous Leukemia, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: * Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) * Decitabine, a chemotherapy drug
Conditions Studied
Interventions
- BIOLOGICAL DC/AML fusion cells
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03679650
The ClinicalTrials.gov registry entry for NCT03679650 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 38 other Acute Myelogenous Leukemia trials with a reported enrollment target (80% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which DC/AML fusion cells is the first listed.
NCT03679650 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03679650 about?
NCT03679650 is a clinical study titled "Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients". This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: * Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) * Decitabine, a chemotherapy d...
What is the current status of trial NCT03679650?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-10-11. Estimated completion is 2026-08-31.
What conditions does trial NCT03679650 study?
This clinical trial studies the following conditions: Acute Myelogenous Leukemia.
What interventions are being tested in trial NCT03679650?
The interventions under investigation include: DC/AML fusion cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03679650?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03679650 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RECRUITING · Phase 1
-
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
COMPLETED · Phase 1
-
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
COMPLETED · Phase 1
-
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.